Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus KLOR CON M20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus KLOR CON M20.
K-LEASE vs KLOR-CON M20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of acid-base balance. Potassium replacement therapy corrects hypokalemia.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
20 mEq potassium chloride orally once daily, adjusted based on serum potassium levels and patient response. Maximum rate of administration: 20 mEq per hour if intravenous; oral doses divided if >20 mEq per dose.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
The terminal elimination half-life of potassium is approximately 8-12 hours in healthy individuals, but is prolonged in renal impairment.
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Potassium is primarily excreted renally (approximately 90%) as potassium ion in urine. A small amount is excreted in feces (about 10%).
Category C
Category C
Potassium Supplement
Potassium Supplement